| scholarly article | Q13442814 |
| P50 | author | Céline Pangault | Q59609247 |
| Michel Cogné | Q30118126 | ||
| P2093 | author name string | Karin Tarte | |
| Marjolein van Egmond | |||
| Daniel Drocourt | |||
| Gérard Tiraby | |||
| Armelle Cuvillier | |||
| Brice Laffleur | |||
| Virginie Pascal | |||
| Arnaud Debin | |||
| Laurent Imbertie | |||
| P2860 | cites work | Activation of the alternative pathway of complement by human serum IgA. | Q54788488 |
| Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies | Q56896403 | ||
| Direct binding of C1q to apoptotic cells and cell blebs induces complement activation | Q56943174 | ||
| Interaction of immunoglobulin A with complement and phagocytic cells | Q69389397 | ||
| Fc alpha receptors mediate release of tumour necrosis factor-alpha and interleukin-6 by human monocytes following receptor aggregation | Q71819211 | ||
| C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited | Q73326011 | ||
| Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells | Q73638542 | ||
| Neutrophil lactoferrin release induced by IgA immune complexes differed from that induced by cross-linking of fcalpha receptors (FcalphaR) with a monoclonal antibody, MIP8a | Q73968562 | ||
| Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies | Q74213454 | ||
| Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene | Q77535970 | ||
| Complement activation plays a key role in the side-effects of rituximab treatment | Q77637131 | ||
| Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18) | Q77850461 | ||
| Monomeric and polymeric IgA show a similar association with the myeloid FcalphaRI/CD89 | Q83288035 | ||
| Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease | Q84500241 | ||
| IgA Fc receptors | Q28202739 | ||
| Structure and function of human IgA Fc receptors (Fc alpha R) | Q28298966 | ||
| HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis | Q33479955 | ||
| Expression of homing receptors on IgA1 and IgA2 plasmablasts in blood reflects differential distribution of IgA1 and IgA2 in various body fluids | Q33725110 | ||
| A novel human IgA monoclonal antibody protects against tuberculosis | Q33800841 | ||
| Multiple roles for the major histocompatibility complex class I- related receptor FcRn | Q33932754 | ||
| The intriguing role of polymorphonuclear neutrophils in antitumor reactions. | Q34128787 | ||
| Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype | Q34434169 | ||
| Activation of the guinea pig alternative complement pathway by mouse IgA immune complexes | Q36346053 | ||
| The function of immunoglobulin A in immunity | Q36346119 | ||
| Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model | Q37484505 | ||
| TRAIL and other TRAIL receptor agonists as novel cancer therapeutics | Q37598582 | ||
| Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. | Q39593092 | ||
| Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies | Q39699202 | ||
| Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies | Q40006850 | ||
| Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors | Q40432649 | ||
| Transepithelial transport of immunoglobulins | Q40661174 | ||
| Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing | Q40694990 | ||
| Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts | Q40695150 | ||
| Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. | Q42940097 | ||
| FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy | Q43447889 | ||
| Human IgA activates the complement system via the mannan-binding lectin pathway | Q43710180 | ||
| Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. | Q44102003 | ||
| Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. | Q45861628 | ||
| In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. | Q46131685 | ||
| Human IgA1 initiates complement-mediated killing of Neisseria meningitidis | Q46912472 | ||
| Complement activation determines the therapeutic activity of rituximab in vivo. | Q47745204 | ||
| Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. | Q53533176 | ||
| Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. | Q54018517 | ||
| Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. | Q54048451 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 1686-1694 | |
| P577 | publication date | 2012-06-11 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells | |
| P478 | volume | 97 |
| Q48223734 | Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. |
| Q33891585 | Exploring Site-Specific N-Glycosylation of HEK293 and Plant-Produced Human IgA Isotypes |
| Q38239286 | Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer |
| Q41704272 | Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy |
| Q64060912 | IgA and FcαRI: Pathological Roles and Therapeutic Opportunities |
| Q91811769 | IgA: Structure, Function, and Developability |
| Q37138332 | Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting |
| Q46027197 | Myeloid cells as effector cells for monoclonal antibody therapy of cancer. |
| Q97643316 | Neutrophil diversity and plasticity in tumour progression and therapy |
| Q41061029 | Neutrophils trigger a NF-κB dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas. |
| Q92248471 | Production, characterization, and in vivo half-life extension of polymeric IgA molecules in mice |
| Q42372842 | Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going? |
Search more.